Meta-analysis of Predictive Value of PD-L1 Levels in the Treatment of PD-(L)1 Inhibitors in Advanced Solid Tumors

Lin Yunyi; Lin Yuhong; Lin Qin

doi:10.3969/j.issn.1004-5775.2024.20.001

Abstract：Objective:To evaluate the predictive value of PD-L1 expression of PD-1 in PD-1/PD-L1 inhibitor treatment of advanced solid tumors.Methods:PubMed,CNKI,WANFANG and other databases were systematically searched to collect studies of PD-(L)1 inhibitors in the treatment of patients with malignant tumors from the establishment of each database to December 28,2022.Two researchers independently evaluated the quality of included studies and extracted data.Stata16.0 and Rev Man5.4 were used for meta-analysis.Results:A total of 20 studies with a total of 12 333 patients were included in this study.The results of meta-analysis showed that there was no statistically significant difference in overall survival(OS)of patients with PD-L1 positive and negative advanced solid tumors treated with PD-(L)1 inhibitors(P＞0.05),and there was also no significant difference in the effectiveness of conventional drug therapy(P＞0.05).Compared with conventional drugs,PD-(L)1 inhibitors significantly prolonged the OS in PD-L1 positive patients and PD-L1 negative patients.Subgroup analysis based on drug target,disease,immunohistochemical score type,and median follow-up time further supported these results was done.Conclusion:The expression status of PD-L1(1％as the cut-off value)is not sufficient to predict OS in patients treated with PD-(L)l inhibitors.PD-L1 positive and negative advanced tumor patients can benefit from inhibitors and conventional drug treatment.Regardless of PD-L1 expression status,PD-(L)1 inhibitors significantly prolong OS in patients with advanced solid tumors compared with conventional drugs.